San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...

Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS SAN JOSE, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Chronix Biomedical ("Chronix") announced today ...

San Jose, California, June 23, 2009 – Chronix Biomedical today reported that a new study in a peer-reviewed journal further confirms the potential diagnostic and prognostic utility of using ...

May 10, 2011, 12:16 PM UTC / Source: GlobeNewswire SALT LAKE CITY, May 10, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement to license ...

IRVINE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ...

Novel, patented copy number index (CNI) therapy monitoring test developed by Chronix complements Oncocyte’s proprietary DetermaIO™ test for immunotherapy treatment selection and may significantly ...

SAN JOSE, Calif. & GÖTTINGEN, Germany--(BUSINESS WIRE)--Chronix Biomedical, Inc., a developer of novel blood-based molecular diagnostics, reports that a review of clinical studies of its Therasure TM ...

Chronix Biomedical, a diagnostic test development company that has operated mostly in secret since its 2000 inception, has finally come out of its shell — publishing information on its product in ...

California's Chronix Biomedical said its cell-free DNA blood test designed to detect residual tumor cells worked successfully in a study involving dogs with breast cancer. The trial builds on a pilot ...

* Chronix Biomedical Inc says it has raised about $5 million in equity financing from total offering amount of amount $5 million - SEC filing Source text Sign up here. Global equities were slightly ...